Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:25 PM
Ignite Modification Date:
2025-12-24 @ 11:25 PM
NCT ID:
NCT00875056
Eligibility Criteria:
Inclusion Criteria:
* Participant has an histopathologically confirmed follicular lymphoma (FL), or other indolent B-cell non-Hodgkin's lymphoma (B-NHL) or mantle cell lymphoma (MCL)
* Only relapsed/refractory FL can be included outside Japan
* Participant has at least one measurable lesion by computerized tomography (CT) scan which is defined by Cheson's 1999 criteria
* Participant has received at least 1 but up to 4 prior chemotherapeutic regimens, the most recent therapy must have failed to induce a partial response, or there must be recurrence in case of the most recent therapy has shown complete response, or there must be relapse in case of the most recent therapy has shown partial response
* Life expectancy of \>4 months
* Participant must have adequate organ and marrow function
* Women of child bearing potential must be negative for pregnancy and agree to use effective contraceptive measures until 30 days after the last dose of MK-0683.
* Men must agree to use effective contraceptive measures until 6 months after the last dose of MK-0683
Exclusion Criteria:
* Participant has undergone allogenic transplant treatment or autologous stem cell transplant within 6 months
* Participant with other active malignancies or central neurological infiltration with lymphoma
* Participant with severe hepatic insufficiency
* Participant with history of allergic reactions attributed to any component of MK-0683
* Participant is known to be human immunodeficiency virus (HIV) antibody-, hepatitis B virus antigen- or hepatitis C virus antibody-positive
* Participant has undergone prior/concomitant treatment with MK-0683 or other histone deacetylase (HDAC) inhibitors
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
74 Years
Study:
NCT00875056
Study Brief:
Protocol Section:
NCT00875056